Treatment Group

# of
Mice

# of
Tumors

Tumor Volume, mm3
(Mean ± SEM)

T-test P-Value
(vs Control )

Normalized Tumor Volume
(Mean ± SEM)

T-test P-Value
vs Control

Day 1

Day 7

Day 14

Day 1

Day 7

Day 14

Day 7

Day 14

Day 7

Day 14

A. Control

38

65

675

±

60

 750

±

64

1095

±

102

1.22

±

0.06

1.86

±

0.19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B. WHI-P131[NP]

17

38

1004

±

98

 755

±

89

666

±

86

0.006

0.969

0.002

0.77

±

0.04

0.70

±

0.06

7.5x10-9

1.5x10-7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

C. Chemo

81

116

518

±

32

635

±

39

748

±

46

0.023

0.125

0.003

1.30

±

0.05

1.57

±

0.07

0.266

0.155

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  C.1 Taxol

27

41

526

±

51

673

±

57

788

±

71

0.059

0.366

0.015

1.47

±

0.10

1.72

±

0.12

0.033

0.516

  C.2 Gemcitabine

34

47

563

±

59

690

±

72

803

±

81

0.184

0.531

0.027

1.26

±

0.09

1.58

±

0.12

0.634

0.211

  C.3 Gefinitib

20

28

433

±

47

487

±

62

599

±

83

0.002

0.004

3.0x10-4

1.12

±

0.08

1.35

±

0.11

0.351

0.020

Table 1: Anti-Cancer Activity of WHI-P131 Nanoparticles in the MMTV/Neu Transgenic Mouse Model of Metastatic HER2+ Breast Cancer. WHI-P131 [NP] (100mg/kg or 150 mg/kg) was administered i.p. daily for 5 consecutive days each week, x 2 weeks; Taxol (6.7 mg/kg) was administered i.p. on days 1,3, and 5; Gemcitabine (33.7 mg/kg) was administered i.p on days 1 and 8; Gefi nitib (75 mg/kg) was administered daily by gavage. Control group included mice that were treated with i.p. injections of WHI-P131-free vehicle, WHI-P131 [NP] at the ineffective 50 mg/kg dose level, or PBS.